Sort   by:  
 Page size 
UnknownSpatiotemporal Dynamics of Coastal Viral Community Structure and Potential Biogeochemical Roles Affected by an Ulva prolifera Green Tide.
Not available
S-EPMC10134843 | biostudies-literature
UnknownGreen synthesis of fluorescent carbon dots from spices for in vitro imaging and tumour cell growth inhibition.
Not available
S-EPMC5827765 | biostudies-literature
UnknownImpact of Green Cosolvents on the Catalytic Dehydrogenation of Formic Acid: The Case of Iridium Catalysts Bearing NHC-phosphane Ligands.
Not available
S-EPMC8527458 | biostudies-literature
UnknownPathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.
Not available
S-EPMC8509647 | biostudies-literature
UnknownCurrent Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy.
Not available
S-EPMC10807511 | biostudies-literature
UnknownMembrane-assisted online renaturation for automated microfluidic lectin blotting.
Not available
S-EPMC3267544 | biostudies-literature
UnknownThe Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
Not available
S-EPMC6433978 | biostudies-literature
TranscriptomicsComparative genomic hybridization of environmental Escherichia coli isolates indicates highly conserved ecophysiology
Escherichia coli, the common inhabitant of the mammalian intestine, exhibits considerable intraspecies genomic variation, which has been suggested to reflect adaptation to different ecological niches. Also, regulatory trade-offs, e.g., between catabolic versatility and stress protection, are thought...
ORGANISM(S): Escherichia coli 
2006-12-04 | E-GEOD-6407 | biostudies-arrayexpress
MetabolomicsFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining ...

2025-02-27 | MTBLS711 | MetaboLights
UnknownA randomized controlled phase II trial of riluzole in early multiple sclerosis.
Not available
S-EPMC4184685 | biostudies-literature
Sort   by:  
 Page size